NeoGenomics, Inc. (NEO)
USD 9.38
(5.39%)
USD 9.38
(5.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 341.25 Million USD | 0.07% |
| 2022 | 341 Million USD | 11.51% |
| 2021 | 305.81 Million USD | 52.99% |
| 2020 | 199.88 Million USD | 8.73% |
| 2019 | 183.83 Million USD | 56.82% |
| 2018 | 117.22 Million USD | 0.25% |
| 2017 | 116.93 Million USD | 12.07% |
| 2016 | 104.34 Million USD | 111.26% |
| 2015 | 49.39 Million USD | 28.3% |
| 2014 | 38.49 Million USD | 34.78% |
| 2013 | 28.56 Million USD | 11.47% |
| 2012 | 25.62 Million USD | 29.18% |
| 2011 | 19.83 Million USD | 5.82% |
| 2010 | 18.74 Million USD | 10.65% |
| 2009 | 16.94 Million USD | 46.74% |
| 2008 | 11.54 Million USD | 26.55% |
| 2007 | 9.12 Million USD | 155.06% |
| 2006 | 3.57 Million USD | 138.89% |
| 2005 | 1.49 Million USD | 110.66% |
| 2004 | 710.77 Thousand USD | 85.72% |
| 2003 | 382.71 Thousand USD | -21.45% |
| 2002 | 487.2 Thousand USD | -93.97% |
| 2001 | 8.07 Million USD | 603.11% |
| 2000 | 1.14 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 89.43 Million USD | -0.83% |
| 2024 Q3 | 95.06 Million USD | 6.29% |
| 2024 Q1 | 90.18 Million USD | 6.15% |
| 2023 Q3 | 84.38 Million USD | -2.69% |
| 2023 Q4 | 84.95 Million USD | 0.68% |
| 2023 FY | 341.25 Million USD | 0.07% |
| 2023 Q1 | 85.2 Million USD | 4.32% |
| 2023 Q2 | 86.71 Million USD | 1.77% |
| 2022 Q3 | 88.4 Million USD | 5.68% |
| 2022 Q1 | 90.26 Million USD | 3.96% |
| 2022 Q4 | 81.67 Million USD | -7.61% |
| 2022 FY | 341 Million USD | 11.51% |
| 2022 Q2 | 83.64 Million USD | -7.33% |
| 2021 Q1 | 56.68 Million USD | 9.18% |
| 2021 Q2 | 75.35 Million USD | 32.95% |
| 2021 Q4 | 86.82 Million USD | -0.15% |
| 2021 FY | 305.81 Million USD | 52.99% |
| 2021 Q3 | 86.95 Million USD | 15.39% |
| 2020 Q4 | 51.91 Million USD | 5.1% |
| 2020 Q2 | 46.91 Million USD | -9.19% |
| 2020 Q1 | 51.66 Million USD | 8.53% |
| 2020 FY | 199.88 Million USD | 8.73% |
| 2020 Q3 | 49.39 Million USD | 5.29% |
| 2019 Q4 | 47.6 Million USD | 0.91% |
| 2019 Q3 | 47.17 Million USD | 6.04% |
| 2019 Q2 | 44.48 Million USD | -0.18% |
| 2019 Q1 | 44.56 Million USD | 29.97% |
| 2019 FY | 183.83 Million USD | 56.82% |
| 2018 Q1 | 24.79 Million USD | -13.43% |
| 2018 Q2 | 29.73 Million USD | 19.91% |
| 2018 Q3 | 28.4 Million USD | -4.49% |
| 2018 Q4 | 34.29 Million USD | 20.74% |
| 2018 FY | 117.22 Million USD | 0.25% |
| 2017 Q3 | 31.11 Million USD | 4.19% |
| 2017 FY | 116.93 Million USD | 12.07% |
| 2017 Q4 | 28.64 Million USD | -7.94% |
| 2017 Q2 | 29.86 Million USD | 9.35% |
| 2017 Q1 | 27.31 Million USD | 2.18% |
| 2016 Q3 | 25.95 Million USD | -1.75% |
| 2016 FY | 104.34 Million USD | 111.26% |
| 2016 Q1 | 25.25 Million USD | 44.76% |
| 2016 Q2 | 26.41 Million USD | 4.6% |
| 2016 Q4 | 26.72 Million USD | 3.0% |
| 2015 Q1 | 10.1 Million USD | -0.47% |
| 2015 Q4 | 17.44 Million USD | 57.76% |
| 2015 Q3 | 11.05 Million USD | 2.52% |
| 2015 FY | 49.39 Million USD | 28.3% |
| 2015 Q2 | 10.78 Million USD | 6.73% |
| 2014 Q4 | 10.15 Million USD | -2.06% |
| 2014 FY | 38.49 Million USD | 34.78% |
| 2014 Q1 | 8.31 Million USD | 4.47% |
| 2014 Q2 | 9.66 Million USD | 16.19% |
| 2014 Q3 | 10.36 Million USD | 7.31% |
| 2013 Q3 | 7.01 Million USD | 5.4% |
| 2013 Q2 | 6.65 Million USD | -4.16% |
| 2013 Q1 | 6.94 Million USD | 11.27% |
| 2013 FY | 28.56 Million USD | 11.47% |
| 2013 Q4 | 7.95 Million USD | 13.52% |
| 2012 Q1 | 6.28 Million USD | 15.12% |
| 2012 FY | 25.62 Million USD | 29.18% |
| 2012 Q4 | 6.23 Million USD | -5.14% |
| 2012 Q2 | 6.52 Million USD | 3.9% |
| 2012 Q3 | 6.57 Million USD | 0.74% |
| 2011 Q2 | 4.77 Million USD | 4.24% |
| 2011 FY | 19.83 Million USD | 5.82% |
| 2011 Q3 | 5.03 Million USD | 5.49% |
| 2011 Q4 | 5.45 Million USD | 8.47% |
| 2011 Q1 | 4.57 Million USD | 2.44% |
| 2010 Q4 | 4.46 Million USD | -8.87% |
| 2010 FY | 18.74 Million USD | 10.65% |
| 2010 Q3 | 4.9 Million USD | 4.03% |
| 2010 Q1 | 4.66 Million USD | -8.16% |
| 2010 Q2 | 4.71 Million USD | 1.01% |
| 2009 FY | 16.94 Million USD | 46.74% |
| 2009 Q3 | 4.25 Million USD | 7.98% |
| 2009 Q4 | 5.07 Million USD | 19.49% |
| 2009 Q1 | 3.67 Million USD | -4.27% |
| 2009 Q2 | 3.93 Million USD | 7.12% |
| 2008 Q2 | 2.55 Million USD | 1.65% |
| 2008 FY | 11.54 Million USD | 26.55% |
| 2008 Q4 | 3.83 Million USD | 45.67% |
| 2008 Q3 | 2.63 Million USD | 3.11% |
| 2008 Q1 | 2.51 Million USD | -27.3% |
| 2007 Q1 | 1.52 Million USD | 7.55% |
| 2007 Q3 | 2.17 Million USD | 5.79% |
| 2007 Q4 | 3.45 Million USD | 58.78% |
| 2007 FY | 9.12 Million USD | 155.06% |
| 2007 Q2 | 2.05 Million USD | 34.99% |
| 2006 Q4 | 1.41 Million USD | 85.24% |
| 2006 FY | 3.57 Million USD | 138.89% |
| 2006 Q3 | 765.68 Thousand USD | -4.54% |
| 2006 Q2 | 802.1 Thousand USD | 35.79% |
| 2006 Q1 | 590.68 Thousand USD | 7.22% |
| 2005 FY | 1.49 Million USD | 110.66% |
| 2005 Q1 | 241.34 Thousand USD | -8.32% |
| 2005 Q4 | 550.92 Thousand USD | 29.79% |
| 2005 Q3 | 424.47 Thousand USD | 51.3% |
| 2005 Q2 | 280.54 Thousand USD | 16.24% |
| 2004 Q3 | 137.09 Thousand USD | 6.56% |
| 2004 Q2 | 128.65 Thousand USD | -29.22% |
| 2004 FY | 710.77 Thousand USD | 85.72% |
| 2004 Q1 | 181.77 Thousand USD | 52.77% |
| 2004 Q4 | 263.26 Thousand USD | 92.03% |
| 2003 Q1 | 83.66 Thousand USD | 105.73% |
| 2003 Q4 | 118.98 Thousand USD | 34.61% |
| 2003 FY | 382.71 Thousand USD | -21.45% |
| 2003 Q3 | 88.39 Thousand USD | -3.59% |
| 2003 Q2 | 91.67 Thousand USD | 9.58% |
| 2002 Q4 | -1.46 Million USD | -309.28% |
| 2002 Q1 | 580.84 Thousand USD | -91.97% |
| 2002 Q3 | 698.12 Thousand USD | 358.62% |
| 2002 FY | 487.2 Thousand USD | -93.97% |
| 2002 Q2 | 152.22 Thousand USD | -73.79% |
| 2001 Q2 | 214.59 Thousand USD | -37.77% |
| 2001 Q4 | 7.23 Million USD | 2398.83% |
| 2001 Q1 | 344.82 Thousand USD | -22.58% |
| 2001 Q3 | 289.34 Thousand USD | 34.83% |
| 2001 FY | 8.07 Million USD | 603.11% |
| 2000 Q2 | 308.04 Thousand USD | 21.6% |
| 2000 Q3 | 142.29 Thousand USD | -53.81% |
| 2000 Q4 | 445.37 Thousand USD | 212.99% |
| 2000 FY | 1.14 Million USD | 0.0% |
| 2000 Q1 | 253.32 Thousand USD | 0.0% |
| 1999 Q1 | 99.04 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| OpGen, Inc. | 30.65 Million USD | -1013.094% |
| Standard BioTools Inc. | 113.48 Million USD | -200.692% |
| Aspira Women's Health Inc. | 24.11 Million USD | -1315.161% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -3793.418% |
| Castle Biosciences, Inc. | 242.78 Million USD | -40.558% |
| Exact Sciences Corporation | 2.06 Billion USD | 83.439% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 68.774% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -2814.492% |
| iSpecimen Inc. | 16.27 Million USD | -1996.495% |
| Inotiv, Inc. | 246.9 Million USD | -38.213% |
| Psychemedics Corporation | 11.33 Million USD | -2910.87% |
| RadNet, Inc. | 268.87 Million USD | -26.917% |
| Prenetics Global Limited | 60.73 Million USD | -461.856% |
| Neuronetics, Inc. | 82.25 Million USD | -314.851% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -1997.173% |
| Exagen Inc. | 52.29 Million USD | -552.577% |
| Bionano Genomics, Inc. | 148.99 Million USD | -129.039% |
| CareDx, Inc | 277.76 Million USD | -22.855% |
| Check-Cap Ltd. | 19.28 Million USD | -1669.337% |
| Twist Bioscience Corporation | 354.18 Million USD | 3.65% |
| Guardant Health, Inc. | 901.62 Million USD | 62.151% |
| Biodesix, Inc. | 77.41 Million USD | -340.786% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -8598.56% |
| Precipio, Inc. | 13.63 Million USD | -2402.214% |
| Natera, Inc. | 938.98 Million USD | 63.657% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -98.511% |
| Sera Prognostics, Inc. | 39.91 Million USD | -754.904% |
| 23andMe Holding Co. | 420.73 Million USD | 18.891% |
| OPKO Health, Inc. | 574.68 Million USD | 40.619% |
| Personalis, Inc. | 128.14 Million USD | -166.304% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -208.755% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -1969.86% |
| T2 Biosystems, Inc. | 41.49 Million USD | -722.413% |
| Neogen Corporation | 405.23 Million USD | 15.79% |
| Myriad Genetics, Inc. | 600.1 Million USD | 43.134% |
| ICON Public Limited Company | 755.64 Million USD | 54.84% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -1997.173% |
| MDxHealth SA | 71.25 Million USD | -378.91% |
| Prenetics Global Limited | 60.73 Million USD | -461.856% |
| Illumina, Inc. | 3.81 Billion USD | 91.05% |
| DarioHealth Corp. | 62.17 Million USD | -448.875% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -3143.614% |
| Medpace Holdings, Inc. | 187.68 Million USD | -81.827% |
| Mainz Biomed B.V. | 27.15 Million USD | -1156.713% |
| Trinity Biotech plc | 46.49 Million USD | -633.954% |
| Sotera Health Company | 300.46 Million USD | -13.574% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -3793.418% |